{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T01:55:52Z","timestamp":1648950952386},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.rmr.2010.05.016","type":"journal-article","created":{"date-parts":[[2011,1,18]],"date-time":"2011-01-18T09:13:24Z","timestamp":1295342004000},"page":"25-31","source":"Crossref","is-referenced-by-count":2,"title":["B\u00e9vacizumab et cancer bronchique\u00a0: population cible en pratique quotidienne"],"prefix":"10.1016","volume":"28","author":[{"given":"V.","family":"Lagnien-Gaume","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Jehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Manzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Jacoulet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Gainet-Brun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Metzger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Pernet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-C.","family":"Polio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-F.","family":"Pugin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Corgne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Amoros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-C.","family":"Dalphin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Westeel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2010.05.016_bib0005","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","article-title":"Cancer statistics, 2007","volume":"57","author":"Jemal","year":"2007","journal-title":"Cancer J Clin"},{"key":"10.1016\/j.rmr.2010.05.016_bib0010","first-page":"7","article-title":"La fr\u00e9quence des cancers en France\u00a0: mortalit\u00e9 en 2003, \u00e9volution depuis 1968\u00a0et cancers de l\u2019enfant","volume":"94","author":"Hill","year":"2007","journal-title":"Bull Cancer"},{"key":"10.1016\/j.rmr.2010.05.016_bib0015","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1378\/chest.07-1358","article-title":"Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes","volume":"132","author":"Spiro Stephen","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2010.05.016_bib0020","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1200\/JCO.2005.04.4859","article-title":"Changing epidemiology of small-cell lung cancer in the United States over the last 30\u00a0years: analysis of the surveillance, epidemiologic and end results database","volume":"24","author":"Govindan","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2010.05.016_bib0025","first-page":"727","article-title":"\u00c9pid\u00e9miologie du cancer bronchique primitif pris en charge dans les centres hospitaliers g\u00e9n\u00e9raux fran\u00e7ais","volume":"19","author":"Blanchon","year":"2002","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.rmr.2010.05.016_bib0030","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/bmj.311.7010.899","article-title":"Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials","volume":"311","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.rmr.2010.05.016_bib0035","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0761-8425(05)85785-7","article-title":"Chimioth\u00e9rapie des cancers bronchiques non \u00e0 petites cellules m\u00e9tastatiques","volume":"22","author":"P\u00e9rol","year":"2005","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.rmr.2010.05.016_bib0040","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer","volume":"22","author":"Johnson","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2010.05.016_bib0045","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2010.05.016_bib0050","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","article-title":"Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil","volume":"27","author":"Reck","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2010.05.016_bib0055","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/annonc\/mdq020","article-title":"Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)","volume":"21","author":"Reck","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.rmr.2010.05.016_bib0060","doi-asserted-by":"crossref","unstructured":"Autorisation de mise sur le march\u00e9 du b\u00e9vacizumab. 2009.","DOI":"10.1016\/S1261-694X(09)73191-8"},{"key":"10.1016\/j.rmr.2010.05.016_bib0065","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1378\/chest.111.6.1710","article-title":"Revisions in the International System for Staging Lung Cancer","volume":"111","author":"Mountain","year":"1997","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2010.05.016_bib0070","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdp590","article-title":"Inter-and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumors","author":"Barlesi","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.rmr.2010.05.016_bib0075","article-title":"Review of pulmonary haemorrhage (PH) in non-small cell lung cancer (NSCLC) patients receiving bevacizumab and cisplatin plus gemcitabine on protocol BO17704 (AVAIL)","author":"Hirsh","year":"2007","journal-title":"ECCO"},{"key":"10.1016\/j.rmr.2010.05.016_bib0080","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1200\/JCO.2008.16.2412","article-title":"Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab","volume":"27","author":"Sandler","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2010.05.016_bib0085","unstructured":"HAS, Commission de la transparence, avis du 14\u00a0mai\u00a02008\u00a0concernant l\u2019AVASTIN. 2008."},{"key":"10.1016\/j.rmr.2010.05.016_bib0090","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.1200\/JCO.2009.23.5622","article-title":"American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small cell lung cancer","volume":"27","author":"Azzoli","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2010.05.016_bib0095","article-title":"MO19390 (SAIL) study group: safety of bevacizumab (BV)-based therapy as first-line treatment of eligible non-small-cell lung cancer (NSCLC) patients (PTS)","volume":"19","author":"Pavlakis","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.rmr.2010.05.016_bib0100","first-page":"100","article-title":"Clinical outcomes (CO) for special populations of patients (PTS) with advanced non-small cell lung cancer (NSCLC): results from ARIES, a bevacizumab (BV) observational cohort study (OCS)","volume":"5","author":"Wozniak","year":"2010","journal-title":"J Thorac Oncol"}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842510005668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842510005668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T23:09:10Z","timestamp":1559948950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761842510005668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0761842510005668"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2010.05.016","relation":{},"ISSN":["0761-8425"],"issn-type":[{"value":"0761-8425","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}